[ In SPAIN, the CSP released its autumn/winter recommendation stating that Nuvaxovid may be used as a booster dose in people aged 18 and older after primary vaccination with mRNA, adenoviral vector, or protein vaccines, regardless of the number of previous booster doses. The CSP recommends a booster dose regardless of the number of doses previously received, at least FIVE MONTHS from the last dose administered.

In ITALY, the MoH released its recommendation extending the use of Nuvaxovid in people aged 18 and older as a homologous booster, and as a heterologous booster after primary vaccination with mRNA or adenoviral vector, where use of an mRNA vaccine is not deemed appropriate.

In FRANCE, the HAS released its recommendation for use of Nuvaxovid as a two-dose primary vaccination series in adolescents aged 12 through 17 who have not yet been vaccinated and who do not wish to, or cannot, receive an mRNA vaccine. The decision builds on existing HAS primary series recommendations in people aged 18 and older, and follows the recent HAS recommendation of Nuvaxovid as a booster dose for people aged 18 and older who no longer wish to, or cannot, receive mRNA vaccines. ]